The Private Healthcare Company

the-phc.co.uk

The Private Healthcare Company Limited are an independent health insurance intermediary with clients throughout the UK and overseas. At the Private Healthcare Company Limited we are very proud of our independent status. Rather than just working for one insurer we work on behalf of our customers, researching the market to find the health insurance products that best suit their requirements. We can provide assistance on a range of different health insurance products including private medical insurance, dental cover and income protection. Additionally we represent all the leading insurers including Bupa, Axa PPP Healthcare, Standard Life Healthcare and WPA as well as the smaller, specialist insurers that offer products exclusively through intermediaries

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

news image

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More

CELL AND GENE THERAPY

TUNE THERAPEUTICS LAUNCHES WITH PIONEERING EPIGENOMIC CONTROL PLATFORM TO MASTER GENE NETWORKS, TREAT BROAD RANGE OF DISEASES

Tune Therapeutics | December 03, 2021

news image

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

Read More

INDUSTRIAL IMPACT

AXION BIOSYSTEMS EXPANDS OPERATIONS WITH ACQUISITION OF M-SOLV MANUFACTURING LIMITED

Axion BioSystems | February 03, 2022

news image

Axion BioSystems, a leading life sciences tools company focused on advanced bioelectronic assay technologies, announces the acquisition of UK-based printed electronics manufacturer M-Solv Manufacturing Limited, a subsidiary of M-Solv Ltd. The creation of the new division, called Axion BioSystems Manufacturing, UK, Ltd., cements the six-year partnership between the companies and positions Axion for continued growth and innovation. “The need to control th...

Read More

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

news image

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More
news image

DOLCAS BIOTECH COMMITS TO ACCELERATING CLEAN-LABEL NUTRACEUTICALS FROM UPCYCLED RAW MATERIALS

PR Newswire | July 24, 2020

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

Read More
news image

CELL AND GENE THERAPY

TUNE THERAPEUTICS LAUNCHES WITH PIONEERING EPIGENOMIC CONTROL PLATFORM TO MASTER GENE NETWORKS, TREAT BROAD RANGE OF DISEASES

Tune Therapeutics | December 03, 2021

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

Read More
news image

INDUSTRIAL IMPACT

AXION BIOSYSTEMS EXPANDS OPERATIONS WITH ACQUISITION OF M-SOLV MANUFACTURING LIMITED

Axion BioSystems | February 03, 2022

Axion BioSystems, a leading life sciences tools company focused on advanced bioelectronic assay technologies, announces the acquisition of UK-based printed electronics manufacturer M-Solv Manufacturing Limited, a subsidiary of M-Solv Ltd. The creation of the new division, called Axion BioSystems Manufacturing, UK, Ltd., cements the six-year partnership between the companies and positions Axion for continued growth and innovation. “The need to control th...

Read More
news image

XYLYX BIO RELEASES NORMAL AND FIBROTIC NATIVECOAT™ ECM SUBSTRATES INCREASE PREDICTIVENESS OF HIGH THROUGHPUT COMPOUND SCREENING

Xylyx Bio | August 27, 2020

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...

Read More